Table 2: Summary of ongoing or unpublished cardiovascular outcome trials.
| Drug | Trial | N | Intervention | Comments | Completion date |
|---|---|---|---|---|---|
| Exenatide in DUROS | FREEDOM-CVO (NCT01455896) | 4,000 | Exenatide in DUROS 60 mcg daily versus placebo | Drug not yet FDA or EMA approved | March 2016 |
| Liraglutide | MAGNA VICTORIA (NCT01761318) | 50 | Liraglutide 0.6-1.8 mg daily versus placebo | March 2016 | |
| Exenatide once-weekly | EXSCEL (NCT01144338) | 14,000 | Exenatide 2 mg weekly versus placebo | September 2017 | |
| Dulaglutide | REWIND (NCT01394952) | 9,622 | Dulaglutide 1.5 mg weekly versus placebo | July 2018 | |
| Albiglutide | HARMONY Outcomes (NCT02465515) | 9,400 | Albiglutide 30 mg or 50 mg weekly versus placebo | May 2019 | |
| Dapagliflozin | DECLARE-TIMI58 (NCT01730534) | 17,276 | Dapagliflozin 10 mg daily versus placebo | April 2019 | |
| Ertugliflozin | VERTIS CV (NCT01986881) | 8,000 | Ertugliflozin 5 mg or 15 mg daily versus placebo | Drug not yet FDA or EMA approved | October 2019 |
| Linagliptin | CAROLINA (NCT01243424) | 6,115 | Linagliptin 5 mg daily versus glimepiride 1-4 mg daily | February 2019 | |
| CARMELINA (NCT01897532) | 8,300 | Linagliptin 5 mg daily versus placebo | January 2018 |
CV = cardiovascular; DPP-4 = dipeptidyl peptidase 4; EMA = European Medicines Agency; FDA = United States Food and Drug Administration; SFU = sulfonylurea.